8-K: Dare Bioscience Faces Nasdaq Delisting Threat After Failing to Meet Minimum Market Value Requirement

Dare Bioscience, Inc. is at risk of being delisted from the Nasdaq Capital Market after failing to meet the minimum market value of listed securities requirement by the February 10, 2025 deadline.

Summary

• Dare Bioscience, Inc. received a notification from Nasdaq on August 12, 2024, stating that it did not meet the minimum market value of listed securities (MVLS) requirement of $35.0 million for continued listing.
• The company was given until February 10, 2025, to regain compliance.
• On February 13, 2025, Nasdaq notified Dare Bioscience that it had not regained compliance and is subject to delisting.
• Dare Bioscience plans to request a hearing before the Nasdaq Hearing Panel to appeal the delisting, which will temporarily halt the delisting process.
• Hearings are typically scheduled 30 to 45 days after the request, and decisions are usually made within 30 days of the hearing.
• There is no guarantee that the Panel will grant an extension or that Dare Bioscience will regain compliance within any granted extension period.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the potential delisting from Nasdaq, indicating financial distress and uncertainty about the company's future.

Positives

• Dare Bioscience is requesting a hearing before the Nasdaq Hearing Panel, which will temporarily stay the delisting of its common stock.
• The company has the opportunity to present its case to the Panel and potentially be granted an extension to regain compliance.

Negatives

• Dare Bioscience failed to meet the minimum market value of listed securities requirement for continued listing on the Nasdaq Capital Market.
• The company is now subject to delisting unless it can successfully appeal the decision before the Nasdaq Hearing Panel.
• There is no assurance that the Panel will grant an extension or that Dare Bioscience will regain compliance within any granted extension period.

Risks

• The Nasdaq Hearing Panel may not grant Dare Bioscience an extension period to regain compliance.
• Even if an extension is granted, Dare Bioscience may not be able to regain compliance with the minimum market value rule within the extension period.
• The hearing may be scheduled, and the Panel may issue a decision, more quickly than expected, which may be unfavorable for the company.
• Failure to maintain listing on the Nasdaq Capital Market could negatively impact the company's stock price and investor confidence.

Future Outlook

The company will request a hearing before the Nasdaq Hearing Panel, but there is no assurance that the Panel will grant the Company any extension period within which to regain compliance with the Minimum MVLS Rule, or if any such extension period is granted, that the Company will regain compliance with the Minimum MVLS Rule within such extension period, or that the Company will be successful in otherwise maintaining the listing of its common stock on The Nasdaq Capital Market.

Management Comments

• The company will timely request a hearing before the Panel, which request will stay the delisting of the company's common stock pending the Panel's decision following the hearing and the expiration of any extension period that the Panel may grant.

Industry Context

Delisting notices are not uncommon, particularly for smaller biotech companies that may face challenges in maintaining market capitalization due to clinical trial outcomes, regulatory hurdles, or funding constraints.

Comparison to Industry Standards

• Many small-cap biotech companies struggle to maintain Nasdaq listing compliance, especially during periods of market volatility or when facing clinical trial setbacks.
• Companies like VBI Vaccines and Ocugen have faced similar delisting warnings in the past, requiring them to implement strategies such as reverse stock splits or capital raises to regain compliance.
• The outcome of Dare Bioscience's hearing will be closely watched by other companies in similar situations, as it could set a precedent for how Nasdaq handles non-compliance cases.

Stakeholder Impact

• Shareholders may experience a decline in the value of their investment if the company is delisted.
• Employees may face uncertainty about their job security if the company's financial situation worsens.
• The company's ability to raise capital and fund its operations may be negatively impacted.

Next Steps

• Dare Bioscience will request a hearing before the Nasdaq Hearing Panel.
• The Nasdaq Hearing Panel will schedule a hearing within 30 to 45 days of the request.
• The Panel will issue a decision within 30 days of the hearing.
• The company will need to regain compliance with the minimum market value rule to avoid delisting.

Key Dates

Keywords

delisting, Nasdaq, minimum market value, compliance, Dare Bioscience, hearing, MVLS